UBS Group
VRAX icon

UBS Group’s Virax Biolabs VRAX Stock Holding History

UBS Group’s Portfolio VRAX Stock Details VRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300
Closed -$2.59K – 11220
2025
Q4 		$2.59K Buy
300
+166
+124% +$2.11K ﹤0.01% 9276
2025
Q3 		$2.04K Buy
+134
New +$2.55K ﹤0.01% 9232
2025
Q2 		– Sell
-897
Closed -$25.6K – 10873
2025
Q1 		$25.6K Sell
897
-620
-41% -$27.3K ﹤0.01% 8054
2024
Q4 		$85.3K Buy
1,517
+696
+85% +$33.3K ﹤0.01% 6974
2024
Q3 		$39.8K Buy
821
+597
+267% +$34.3K ﹤0.01% 6964
2024
Q2 		$6.5K Buy
224
+121
+117% +$3K ﹤0.01% 7914
2024
Q1 		$1.85K Buy
103
+76
+281% +$1.77K ﹤0.01% 8034
2023
Q4 		$971 Buy
27
+26
+2,600% +$1.52K ﹤0.01% 8454
2023
Q3 		$48 Buy
+1
New +$94 ﹤0.01% 9010
2023
Q2 		– Sell
-12
Closed -$2.13K – 9707
2023
Q1 		$2.13K Sell
12
-13
-52% -$2.53K ﹤0.01% 8570
2022
Q4 		$4.51K Sell
25
-24
-49% -$8.53K ﹤0.01% 9325
2022
Q3 		$38K Buy
+49
New +$81K ﹤0.01% 6619

Other funds holding VRAX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group's VRAX Position: Q1 2026 in Review

UBS Group sold out of Virax Biolabs (VRAX) in Q1 2026, closing a stake of 300 shares — an estimated $2.59K sold.

UBS Group first reported a position in VRAX in Q3 2022 and held it in 12 quarters. The position peaked at $85.3K in Q4 2024. 4 funds tracked by Wall St. Rank hold VRAX as of Q1 2026.

  • UBS Group reported no remaining Virax Biolabs position as of Q1 2026 after selling out during the quarter.
  • UBS Group sold 300 Virax Biolabs shares in Q1 2026, an estimated $2.59K.
  • UBS Group first reported a position in Virax Biolabs in Q3 2022 and held it in 12 quarters.
  • UBS Group's Virax Biolabs position peaked at $85.3K in Q4 2024.
  • 4 funds tracked by Wall St. Rank held Virax Biolabs as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.